Last reviewed · How we verify
5-fluorouracil,leucovorin,panitumumab
This combination uses 5-fluorouracil and leucovorin as chemotherapy agents to inhibit thymidylate synthase and enhance fluorouracil cytotoxicity, while panitumumab blocks EGFR signaling to prevent tumor cell growth and survival.
This combination uses 5-fluorouracil and leucovorin as chemotherapy agents to inhibit thymidylate synthase and enhance fluorouracil cytotoxicity, while panitumumab blocks EGFR signaling to prevent tumor cell growth and survival. Used for Metastatic colorectal cancer (Phase 2 investigation).
At a glance
| Generic name | 5-fluorouracil,leucovorin,panitumumab |
|---|---|
| Sponsor | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
| Drug class | Chemotherapy combination with EGFR inhibitor |
| Target | Thymidylate synthase (5-FU), EGFR (panitumumab) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
5-fluorouracil (5-FU) is a pyrimidine antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis. Leucovorin (folinic acid) enhances 5-FU efficacy by stabilizing the 5-FU–thymidylate synthase complex. Panitumumab is a fully human monoclonal antibody targeting epidermal growth factor receptor (EGFR), blocking ligand-induced receptor activation and downstream proliferation signaling. Together, these agents provide dual mechanisms targeting DNA synthesis and growth factor signaling in colorectal cancer cells.
Approved indications
- Metastatic colorectal cancer (Phase 2 investigation)
Common side effects
- Diarrhea
- Neutropenia
- Mucositis
- Skin rash (panitumumab-related)
- Nausea/vomiting
- Fatigue
Key clinical trials
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations (PHASE3)
- Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (PHASE3)
- A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer (PHASE2)
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (PHASE3)
- Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC (PHASE2)
- Botensilimab and Balstilimab Optimization in Colorectal Cancer (PHASE2)
- Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: